Carbon ion radiotherapy for 80 years or older patients with hepatocellular carcinoma

BMC Cancer

Research Article

Yoshinori Koyama¹  Ken Shirabe²  Satoru Kakizaki³  Shintaro Shiba⁴  Kei Shibuya⁴  Takanori Abe⁴  Takashi Nakano⁴  Hiroyuki Kuwano⁵  Hiroyuki Katoh⁶  Tatsuya Ohno⁶  Hirohumi Shimada⁶ 

[1] Department of Diagnostic Radiology, Shibukawa Medical Center, Shibukawa, Gunma, Japan;Department of Hepato-Biliary and Pancreatic surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan;Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan;Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Syowa-machi, 371-8511, Maebashi, Gunma, Japan;Department of Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan;Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan;

关键词: Carbon-ion radiotherapy;    Hepatocellular carcinoma;    Elderly patients;    Radiotherapy;   

DOI  :  10.1186/s12885-017-3724-4

 received in 2016-10-28, accepted in 2017-10-30,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundTo evaluate the safety and efficacy of carbon ion radiotherapy (C-ion RT) for 80 years or older patients with hepatocellular carcinoma (HCC).MethodsEligibility criteria of this retrospective study were: 1) HCC confirmed by histology or typical hallmarks of HCC by imaging techniques of four-phase multidetector-row computed tomography or dynamic contrast-enhanced magnetic resonance imaging; 2) no intrahepatic metastasis or distant metastasis; 3) no findings suggesting direct infiltration of the gastrointestinal tract; 4) performance status ≤2 by Eastern Cooperative Oncology Group classification; and 5) Child-Pugh classification A or B. Patients received C-ion RT with 52.8 Gy (RBE) or 60.0 Gy (RBE) in four fractions for usual cases and 60.0 Gy (RBE) in 12 fractions for close-to-gastrointestinal tract cases. Toxicities were classified using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (Version 4.0).ResultsBetween March 2011 and November 2015, 31 patients were treated. The median follow-up period of all patients was 23.2 months (range: 8.4–55.3 months). Median age at the time of registration of C-ion RT was 83 years (range: 80–95 years). Child-Pugh grade A and B were 27 patients and 4 patients, respectively.The 2-year estimated overall survival, local control, and progression-free survival rates were 82.3%, 89.2%, and 51.3%, respectively. No patients had Grade 2 or higher acute toxicities (within 3 months after C-ion RT). One patient experienced progression in Child-Pugh classification from A to B within 3 months after C-ion RT. In late toxicities, Grade 3 encephalopathy was observed in 3 patients, and 2 improved with medication.ConclusionsC-ion RT was effective with minimal toxicities for 80 years or older patients with hepatocellular carcinoma.Trial registrationUMIN000020571: date of registration, 14 January 2016, retrospectively registered.

【 授权许可】

CC BY   
© The Author(s). 2017